Top Markets
Coin of the day
Solvonis Therapeutics plc Solvonis Therapeutics plc

Solvonis Therapeutics plc

SVNS
Classifica tra le azioni #40469
Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January... Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January 2025, is dedicated to the research and development of advanced polymer modification technologies and techniques. Its operations span the United Kingdom, Slovenia, and across Europe. The company offers a diverse portfolio of specialized products: GRAFTABOND: A line of graft/block copolymers designed to robustly combine various polymers with materials such as fiberglass, carbon fiber, mineral and natural fillers, and even mixed polymer waste. GRAFTALEN: These are reactive solid super-concentrates engineered to enhance polyolefin rheology, boost e-modulus, act as chain extenders for PET/PBT, and serve as AOX masterbatches. GRAFTAPOR: Comprising porous polymer-carriers, this line is specifically developed for applications involving liquid chemicals. GRAFTAMID: This series includes high-temperature elastomers, based on nanostructured polyolefin-polyamide alloys. They function as advanced hardening modifiers within polyamide compounds or as standalone components in hot melt adhesive formulations. GRAFTAKIT: Offering reactive liquid or solid super-concentrates embedded in polymeric porous media, GRAFTAKIT is used to optimize reaction extrusion and the modification of compounds. GRAFTALLOY: A range of polymer-polymer nano-alloys crafted to significantly improve abrasion and temperature resistance, boost impact strength, and reduce friction. GRAFTASYNT: This line encompasses synthetic products, notably including halogen-free flame retardants. GRAFTAMER: An innovative smart polymer characterized by thermo-reversible crosslinking, self-hardening, self-healing properties, and shape memory capabilities. The company was founded in 2017 and maintains its headquarters in London, United Kingdom.
Prezzo delle azioni
$0.00204105
Capitalizzazione di mercato
$138.92K
Variazione (1 giorno)
5.63%
Variazione (1 anno)
-60.44%
Paese
GB
Scambia Solvonis Therapeutics plc (SVNS)

Categoria

Margine operativo per Solvonis Therapeutics plc (SVNS)
Margine operativo al 2026 TTM: 0.00%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Solvonis Therapeutics plc, il margine operativo attuale (TTM) è 0.00%. Alla fine del 2026, il margine operativo era 0.00%.
Storico del margine operativo per Solvonis Therapeutics plc da 2026 a 2026
Margine operativo alla fine di ogni anno
Anno Margine Operativo Cambia
Non abbastanza dati per le date fornite.
Margine operativo per aziende simili o concorrenti
Azienda Margine Operativo Differenza del margine operativo Il paese
0.00% -
US
11.56% -
DE
0.00% -
FR
0.00% -
DE
20.87% -
US
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.